Farmaci biologici anti-TNFa — Concorso SSM MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Infliximab
L'infliximab è un anticorpo monoclonale chimerico anti-TNFa approvato per Crohn e colite ulcerosa. Rituximab e anti-CD20, bevacizumab anti-VEGF.
Reference: Linee guida ECCO 2023 - Malattia di Crohn